Zobrazeno 1 - 10
of 10
pro vyhledávání: '"van Bussel MTJ"'
Autor:
van Kampen E; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands., van Bussel MTJ; College ter Beoordeling van Geneesmiddelen, Dutch Medicines Evaluation Board (CBG-MEB), Graadt van Roggenweg 500, 3531 AH Utrecht, the Netherlands., Oude Munnink TH; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands., Touw DJ; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands., Broekman KE; College ter Beoordeling van Geneesmiddelen, Dutch Medicines Evaluation Board (CBG-MEB), Graadt van Roggenweg 500, 3531 AH Utrecht, the Netherlands; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands. Electronic address: k.e.broekman@umcg.nl.
Publikováno v:
Journal of geriatric oncology [J Geriatr Oncol] 2023 Nov; Vol. 14 (8), pp. 101636. Date of Electronic Publication: 2023 Oct 06.
Autor:
Maliepaard M; Dutch Medicines Evaluation Board (CBG-MEB), College ter Beoordeling van Geneesmiddelen, Utrecht, The Netherlands.; Department of Pharmacology and Toxicology, Radboud University Medical Centre, Nijmegen, The Netherlands., Faber YS; Dutch Medicines Evaluation Board (CBG-MEB), College ter Beoordeling van Geneesmiddelen, Utrecht, The Netherlands., van Bussel MTJ; Dutch Medicines Evaluation Board (CBG-MEB), College ter Beoordeling van Geneesmiddelen, Utrecht, The Netherlands.
Publikováno v:
Pharmacology research & perspectives [Pharmacol Res Perspect] 2023 Apr; Vol. 11 (2), pp. e01067.
Autor:
Tabernero J; Vall d'Hebron Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain., Van Cutsem E; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium., Garralda E; START Madrid, Hospital Universitario HM Sanchinarro, Madrid, Spain., Tai D; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., De Braud F; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Geva R; Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel., van Bussel MTJ; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Fiorella Dotti K; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Elez E; Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain., de Miguel MJ; START Madrid, Hospital Universitario HM Sanchinarro, Madrid, Spain., Litwiler K; Pfizer, Boulder, CO, USA., Murphy D; Pfizer, La Jolla, CA, USA., Edwards M; Pfizer, New York, NY, USA., Morris VK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
The oncologist [Oncologist] 2023 Mar 17; Vol. 28 (3), pp. 230-238.
Autor:
Maliepaard M; College ter Beoordeling van Geneesmiddelen, Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, the Netherlands; Department of Pharmacology and Toxicology, Radboud University Medical Centre, Nijmegen, the Netherlands., Carree W; College ter Beoordeling van Geneesmiddelen, Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, the Netherlands., van Bussel MTJ; College ter Beoordeling van Geneesmiddelen, Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, the Netherlands. Electronic address: m.v.bussel@cbg-meb.nl.
Publikováno v:
ESMO open [ESMO Open] 2021 Dec; Vol. 6 (6), pp. 100301. Date of Electronic Publication: 2021 Nov 06.
Autor:
van Bussel MTJ; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. m.v.bussel@nki.nl., Awada A; Oncology Medicine Department, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium., de Jonge MJA; Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Mau-Sørensen M; Department of Oncology, Rigshospitalet, Copenhagen, Denmark., Nielsen D; Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark., Schöffski P; Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium., Verheul HMW; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Sarholz B; Merck KGaA, Darmstadt, Germany., Berghoff K; Merck KGaA, Darmstadt, Germany., El Bawab S; Merck KGaA, Darmstadt, Germany., Kuipers M; Merck KGaA, Darmstadt, Germany., Damstrup L; Merck KGaA, Darmstadt, Germany.; Debiopharm International S.A., Lausanne, Switzerland., Diaz-Padilla I; Ares Trading S.A., Eysins, Switzerland; an Affiliate of Merck KGaA, Darmstadt, Germany., Schellens JHM; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Synthon Biopharmaceuticals, Nijmegen, The Netherlands.
Publikováno v:
British journal of cancer [Br J Cancer] 2021 Feb; Vol. 124 (4), pp. 728-735. Date of Electronic Publication: 2020 Nov 24.
Autor:
van Bussel MTJ; From the Division of Pharmacology (M.T.J.v.B., D.P., B.M.K., J.H.B., J.H.M.S.), Clinical Pharmacology (M.T.J.v.B., B.M.K., J.H.B., J.H.M.S), Division of Pathology (M.B.), Department of Biometrics (K.S.), Department of Laboratory Medicine (D.T.C.L., D.v.d.B.), and Department of Neuro-oncology (D.B.), Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; and Science Faculty (J.H.B., J.H.M.S), Pharmaceutical Sciences, Division of Pharmaco-epidemiology and Clinical Pharmacology, Utrecht University, the Netherlands., Pluim D; From the Division of Pharmacology (M.T.J.v.B., D.P., B.M.K., J.H.B., J.H.M.S.), Clinical Pharmacology (M.T.J.v.B., B.M.K., J.H.B., J.H.M.S), Division of Pathology (M.B.), Department of Biometrics (K.S.), Department of Laboratory Medicine (D.T.C.L., D.v.d.B.), and Department of Neuro-oncology (D.B.), Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; and Science Faculty (J.H.B., J.H.M.S), Pharmaceutical Sciences, Division of Pharmaco-epidemiology and Clinical Pharmacology, Utrecht University, the Netherlands., Milojkovic Kerklaan B; From the Division of Pharmacology (M.T.J.v.B., D.P., B.M.K., J.H.B., J.H.M.S.), Clinical Pharmacology (M.T.J.v.B., B.M.K., J.H.B., J.H.M.S), Division of Pathology (M.B.), Department of Biometrics (K.S.), Department of Laboratory Medicine (D.T.C.L., D.v.d.B.), and Department of Neuro-oncology (D.B.), Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; and Science Faculty (J.H.B., J.H.M.S), Pharmaceutical Sciences, Division of Pharmaco-epidemiology and Clinical Pharmacology, Utrecht University, the Netherlands., Bol M; From the Division of Pharmacology (M.T.J.v.B., D.P., B.M.K., J.H.B., J.H.M.S.), Clinical Pharmacology (M.T.J.v.B., B.M.K., J.H.B., J.H.M.S), Division of Pathology (M.B.), Department of Biometrics (K.S.), Department of Laboratory Medicine (D.T.C.L., D.v.d.B.), and Department of Neuro-oncology (D.B.), Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; and Science Faculty (J.H.B., J.H.M.S), Pharmaceutical Sciences, Division of Pharmaco-epidemiology and Clinical Pharmacology, Utrecht University, the Netherlands., Sikorska K; From the Division of Pharmacology (M.T.J.v.B., D.P., B.M.K., J.H.B., J.H.M.S.), Clinical Pharmacology (M.T.J.v.B., B.M.K., J.H.B., J.H.M.S), Division of Pathology (M.B.), Department of Biometrics (K.S.), Department of Laboratory Medicine (D.T.C.L., D.v.d.B.), and Department of Neuro-oncology (D.B.), Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; and Science Faculty (J.H.B., J.H.M.S), Pharmaceutical Sciences, Division of Pharmaco-epidemiology and Clinical Pharmacology, Utrecht University, the Netherlands., Linders DTC; From the Division of Pharmacology (M.T.J.v.B., D.P., B.M.K., J.H.B., J.H.M.S.), Clinical Pharmacology (M.T.J.v.B., B.M.K., J.H.B., J.H.M.S), Division of Pathology (M.B.), Department of Biometrics (K.S.), Department of Laboratory Medicine (D.T.C.L., D.v.d.B.), and Department of Neuro-oncology (D.B.), Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; and Science Faculty (J.H.B., J.H.M.S), Pharmaceutical Sciences, Division of Pharmaco-epidemiology and Clinical Pharmacology, Utrecht University, the Netherlands., van den Broek D; From the Division of Pharmacology (M.T.J.v.B., D.P., B.M.K., J.H.B., J.H.M.S.), Clinical Pharmacology (M.T.J.v.B., B.M.K., J.H.B., J.H.M.S), Division of Pathology (M.B.), Department of Biometrics (K.S.), Department of Laboratory Medicine (D.T.C.L., D.v.d.B.), and Department of Neuro-oncology (D.B.), Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; and Science Faculty (J.H.B., J.H.M.S), Pharmaceutical Sciences, Division of Pharmaco-epidemiology and Clinical Pharmacology, Utrecht University, the Netherlands., Beijnen JH; From the Division of Pharmacology (M.T.J.v.B., D.P., B.M.K., J.H.B., J.H.M.S.), Clinical Pharmacology (M.T.J.v.B., B.M.K., J.H.B., J.H.M.S), Division of Pathology (M.B.), Department of Biometrics (K.S.), Department of Laboratory Medicine (D.T.C.L., D.v.d.B.), and Department of Neuro-oncology (D.B.), Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; and Science Faculty (J.H.B., J.H.M.S), Pharmaceutical Sciences, Division of Pharmaco-epidemiology and Clinical Pharmacology, Utrecht University, the Netherlands., Schellens JHM; From the Division of Pharmacology (M.T.J.v.B., D.P., B.M.K., J.H.B., J.H.M.S.), Clinical Pharmacology (M.T.J.v.B., B.M.K., J.H.B., J.H.M.S), Division of Pathology (M.B.), Department of Biometrics (K.S.), Department of Laboratory Medicine (D.T.C.L., D.v.d.B.), and Department of Neuro-oncology (D.B.), Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; and Science Faculty (J.H.B., J.H.M.S), Pharmaceutical Sciences, Division of Pharmaco-epidemiology and Clinical Pharmacology, Utrecht University, the Netherlands., Brandsma D; From the Division of Pharmacology (M.T.J.v.B., D.P., B.M.K., J.H.B., J.H.M.S.), Clinical Pharmacology (M.T.J.v.B., B.M.K., J.H.B., J.H.M.S), Division of Pathology (M.B.), Department of Biometrics (K.S.), Department of Laboratory Medicine (D.T.C.L., D.v.d.B.), and Department of Neuro-oncology (D.B.), Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; and Science Faculty (J.H.B., J.H.M.S), Pharmaceutical Sciences, Division of Pharmaco-epidemiology and Clinical Pharmacology, Utrecht University, the Netherlands. d.brandsma@nki.nl.
Publikováno v:
Neurology [Neurology] 2020 Feb 04; Vol. 94 (5), pp. e521-e528. Date of Electronic Publication: 2020 Jan 06.
Autor:
van Bussel MTJ; Division of Pharmacology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. m.v.bussel@nki.nl.; Department of Medical Oncology & Clinical Pharmacology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. m.v.bussel@nki.nl., Beijnen JH; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands., Brandsma D; Department of Neuro-oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Publikováno v:
BMC cancer [BMC Cancer] 2019 May 30; Vol. 19 (1), pp. 519. Date of Electronic Publication: 2019 May 30.
Autor:
Pluim D; Division of Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, the Netherlands. Electronic address: d.pluim@nki.nl., Ros W; Division of Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, the Netherlands; Department of Clinical Pharmacology, NKI-AVL, Amsterdam, the Netherlands., van Bussel MTJ; Division of Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, the Netherlands; Department of Clinical Pharmacology, NKI-AVL, Amsterdam, the Netherlands., Brandsma D; Department of Neuro-Oncology NKI-AVL, Amsterdam, the Netherlands., Beijnen JH; Department of Pharmacy and Pharmacology, NKI-AVL, Amsterdam, the Netherlands; Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands., Schellens JHM; Division of Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, the Netherlands; Department of Clinical Pharmacology, NKI-AVL, Amsterdam, the Netherlands; Department of Pharmacy and Pharmacology, NKI-AVL, Amsterdam, the Netherlands; Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands; Division of Medical Oncology, NKI-AVL, Amsterdam, the Netherlands.
Publikováno v:
Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2019 Feb 05; Vol. 164, pp. 128-134. Date of Electronic Publication: 2018 Oct 17.
Autor:
van Bussel MTJ; Department of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Medical Oncology & Clinical Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Pluim D; Department of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Bol M; Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Beijnen JH; Department of Medical Oncology & Clinical Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Division of Pharmacoepidemiology & Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands., Schellens JHM; Department of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Medical Oncology & Clinical Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Division of Pharmacoepidemiology & Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands., Brandsma D; Department of Neuro-oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. d.brandsma@nki.nl.
Publikováno v:
Journal of neuro-oncology [J Neurooncol] 2018 Mar; Vol. 137 (1), pp. 1-10. Date of Electronic Publication: 2017 Nov 30.
Autor:
Rood JJM; Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands. Electronic address: j.j.m.rood@uu.nl., van Bussel MTJ; The Netherlands Cancer Institute, Division of Molecular Pathology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Schellens JHM; Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands; The Netherlands Cancer Institute, Department of Clinical Pharmacology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Beijnen JH; Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands; The Netherlands Cancer Institute, Department of Clinical Pharmacology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; MC Slotervaart, Department of Pharmacy & Pharmacology, Louwesweg 6, 1066 EC Amsterdam, The Netherlands., Sparidans RW; Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands; Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Chemical Biology & Drug Development, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands.
Publikováno v:
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences [J Chromatogr B Analyt Technol Biomed Life Sci] 2016 Sep 15; Vol. 1031, pp. 80-85. Date of Electronic Publication: 2016 Jul 18.